NCT07525258 Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
| NCT ID | NCT07525258 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-04-05 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-04-05 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.
Eligibility Criteria
Inclusion Criteria: * Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system. Exclusion Criteria: * Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Contact & Investigator
Lamia Haque
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT07525258 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07525258 currently recruiting?
Yes, NCT07525258 is actively recruiting participants. Contact the research team at lamia.haque@yale.edu for enrollment information.
Where is the NCT07525258 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT07525258 clinical trial?
NCT07525258 is sponsored by Yale University. The principal investigator is Lamia Haque at Yale University. The trial plans to enroll 30 participants.